Mon, Jul 28, 2014, 3:52 AM EDT - U.S. Markets open in 5 hrs 38 mins

Recent

% | $
Click the to save as a favorite.

MannKind Corp. Message Board

  • stocktipster stocktipster Jun 23, 2012 10:05 AM Flag

    $12.00 In Twelve Months

     

    Twelve month run-up to the Afrezza approval in conjunction with a "big pharma" marketing partnership for Afrezza, another development partnership for one of the cancer drugs, and several Technosphere license agreements with other drug companies moves the share price to the $12.00 range or higher within a year.

    Check the one year chart on MDVN.

    The annual market for drugs to treat diabetes just in the United States will be over $55 billion dollar by the year 2020. The world wide market will be ten times that amount.

    Mannkind is currently substantially undervalued.

    TheStreet.com is correct that Mannkind is due for a technical breakout. I suggest you buy a few shares before you miss the gap higher and the subsequent approval run.

    This topic is deleted.
 
MNKD
8.775-0.225(-2.50%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEFri, Jul 25, 2014 4:01 PM EDT
Sohu.com Inc.
NasdaqGSFri, Jul 25, 2014 3:59 PM EDT